- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cancer Genetics Reports Q2 Financial Results
Cancer Genetics (NASDAQ:CGIX) has released its second quarter results for the quarter ended June 30, 2019. As quoted in the press release: RECENT STRATEGIC AND OPERATIONAL HIGHLIGHTS Completed divestiture of two operating units for cash, notes and future payment streams Consolidated operational focus on drug discovery and preclinical service business of vivoPharm Increased Discovery Services …
Cancer Genetics (NASDAQ:CGIX) has released its second quarter results for the quarter ended June 30, 2019.
As quoted in the press release:
RECENT STRATEGIC AND OPERATIONAL HIGHLIGHTS
- Completed divestiture of two operating units for cash, notes and future payment streams
- Consolidated operational focus on drug discovery and preclinical service business of vivoPharm
- Increased Discovery Services revenue in Q2 2019 by 19.1%, compared to same period of 2018
- Continuing to explore strategic alternatives for future sale of other assets, merger, reverse merger or other strategic transactions
“We are very pleased with the progress we have made in improving the Company’s financial condition through the divestiture of certain corporate assets, giving the Company time to explore a variety of new strategic alternatives,” said John A. Roberts, Chief Executive Officer of Cancer Genetics. “Also, during the second quarter, we delivered an increase in revenue growth of 19.1% from our remaining Discovery Services business unit, while reducing the combined quarterly cost of revenue from continuing operations by $0.4 million.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.